Noreen Scherer
Chief Tech/Sci/R&D Officer presso LARIMAR THERAPEUTICS, INC.
Profilo
Noreen Scherer is currently the Vice President-Clinical Operations at Larimar Therapeutics, Inc. and Alcobra, Inc. She previously held the same position at Chondrial Therapeutics, Inc. Ms. Scherer completed her undergraduate degree at LaSalle University.
Posizioni attive di Noreen Scherer
| Società | Posizione | Inizio |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
| Alcobra, Inc. | Chief Operating Officer | - |
Precedenti posizioni note di Noreen Scherer
| Società | Posizione | Fine |
|---|---|---|
Chondrial Therapeutics, Inc.
 Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Chief Tech/Sci/R&D Officer | - |
Formazione di Noreen Scherer
| LaSalle University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| LARIMAR THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Chondrial Therapeutics, Inc.
Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Alcobra, Inc. |
- Borsa valori
- Insiders
- Noreen Scherer
